Bortezomib is a proteasome inhibitor has ability to induced expression of COOH-terminal region but not the whole CD20molecule. One more report revealed that prolonged (48 hours) incubation with bortezomib lead to a significant decreasein levels of CD20 on cell surface as well as R-CDC. Moreover, these effects may be partly reversed by bafilomycin A1, aninhibitor of lysosomal/autophagosomal pathway of protein degradation.